MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language—backed by an integrated, full-stack wet lab that closes the loop from insight to validated candidate. Our platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics. With 25 billion+ biological relationships indexed and 15+ molecules advanced to clinic, MindWalk partners with 19 of the top 20 pharmaceutical companies to accelerate precision discovery. As an investor in MindWalk, you're joining a company at the forefront of the TechBio revolution—where AI-native approaches are reshaping how therapeutics are discovered, developed, and delivered.

Learn more